Immune Checkpoint Blockade Anti–PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome

CONTEXT: The programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) pathway is a key regulator in T-cell activation and tolerance, limiting effector T-cell function in peripheral tissues. Atezolizumab, an anti–PD-L1 monoclonal antibody, is approved for treatment of som...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Endocr Soc
Main Authors: Lanzolla, Giulia, Coppelli, Alberto, Cosottini, Mirco, Del Prato, Stefano, Marcocci, Claudio, Lupi, Isabella
Formato: Artigo
Idioma:Inglês
Publicado: Endocrine Society 2019
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6364624/
https://ncbi.nlm.nih.gov/pubmed/30746508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2018-00366
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares